| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444134 | European Journal of Cancer | 2013 | 7 Pages |
Abstract
Within the context of a publicly funded health care system, the Recurrence Score assay significantly affects adjuvant treatment recommendations and is cost effective in ER+ node negative breast cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
J.A. Davidson, I. Cromwell, S.L. Ellard, C. Lohrisch, K.A. Gelmon, T. Shenkier, D. Villa, H. Lim, S. Sun, S. Taylor, M. Taylor, B. Czerkawski, M. Hayes, D.N. Ionescu, C. Yoshizawa, C. Chao, S. Peacock, S.K. Chia,